Introduction to whether brigatinib has been included in the medical insurance reimbursement catalog

Brigatinib (also known as Brigatinib) is a new generation of ALK inhibitors, mainly used to treat patients with ALK fusion gene-positive non-small cell lung cancer (NSCLC). As an important member of targeted therapy drugs, brigatinib has strong ability to control drug resistance, especially for patients who are resistant to crizotinib. At present, this drug has been successfully launched in China and has been included in the national medical insurance reimbursement catalog, which has greatly reduced the patient's medication burden.

In the domestic market, the common specifications of brigatinib are 90mg or 180mg tablets. After medical insurance negotiations, the price has dropped significantly. The price per box is about four to five thousand yuan, which is far lower than its original selling price when it was launched. Through the national medical insurance reimbursement policy, the proportion of patients paying out-of-pocket has been significantly reduced. Especially in some areas, with the urban and rural residents' medical insurance or employee medical insurance, the actual payment may be lower, effectively reducing the long-term financial pressure of medication for patients with mid-to-late stage lung cancer.

Although domestic prices have been significantly reduced through medical insurance regulation, overseas generic drugs are still attractive to some patients with tight financial conditions. Currently, generic drugs of brigatinib are produced and sold in Laos and other places. Its ingredients are basically the same as the original drug, but the price is more affordable, with each box only costing a few hundred yuan. This type of generic drugs has become one of the choices for some patients to purchase drugs overseas. However, when choosing generic drugs, you should ensure that the source of the drugs is regular and safe.

Overall, brigatinib has become one of the affordable targeted therapy options for domestic patients due to its significant efficacy in ALK positive lung cancer and the support of national medical insurance. For drug users, choosing the appropriate version (original research or generic) under the guidance of a doctor, and reasonable reimbursement combined with medical insurance policies will help smooth long-term treatment and maintain quality of life.

Reference: https://go.drugbank.com/drugs/

xa0